The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Kidney Injury
Interventions
DRUG

dapagliflozin

Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.

OTHER

Other anti-diabetic drug or no anti-diabetic drug

"Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist."

DRUG

empagliflozin

Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.

DRUG

canagliflozin

Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

lead

National Taiwan University Hospital

OTHER